Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement

Christine E. Ryan; Rebecca L. Zon; Robert Redd; David C. Fisher; Roni Shouval; Anita Kumar; Jennifer L. Crombie; Hossein Sadrzadeh; Austin I. Kim; Lakshmi Nayak; Ugonma N. Chukwueke; Caron A. Jacobson; Matthew J. Frigault; M. Lia Palomba; Philippe Armand; Zachary Epstein-Peterson; Reid W. Merryman

doi:10.1111/bjh.19037

Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement

Christine E. Ryan, Rebecca L. Zon, Robert Redd, David C. Fisher, Roni Shouval, Anita Kumar, Jennifer L. Crombie, Hossein Sadrzadeh, Austin I. Kim, Lakshmi Nayak, Ugonma N. Chukwueke, Caron A. Jacobson, Matthew J. Frigault, M. Lia Palomba, Philippe Armand, Zachary Epstein-Peterson, Reid W. Merryman

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.

Original language	English
Pages (from-to)	774-780
Number of pages	7
Journal	British Journal of Haematology
Volume	203
Issue number	5
Early online date	16 Aug 2023
DOIs	https://doi.org/10.1111/bjh.19037
State	Published - Dec 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023 British Society for Haematology and John Wiley & Sons Ltd.

Funding

The authors would like to thank the nursing staff and clinical research teams at all the participating centres. C.E.R. gratefully acknowledges support from the Lymphoma Research Foundation Clinical Research Mentoring Program and a CLL Society Young Investigator Award. R.S. acknowledges support from the Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748) from the National Institutes of Health/National Cancer Institute. M.J.F. would also like to thank the Karrie Kapoor Fund for Cellular Immunotherapy. The authors would like to thank the nursing staff and clinical research teams at all the participating centres. C.E.R. gratefully acknowledges support from the Lymphoma Research Foundation Clinical Research Mentoring Program and a CLL Society Young Investigator Award. R.S. acknowledges support from the Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748) from the National Institutes of Health/National Cancer Institute. M.J.F. would also like to thank the Karrie Kapoor Fund for Cellular Immunotherapy.

Funders	Funder number
CLL Society	P30 CA008748
Karrie Kapoor Fund for Cellular Immunotherapy
National Institutes of Health
National Cancer Institute

Keywords

CNS
cellular therapies
non-Hodgkin lymphoma

Access to Document

10.1111/bjh.19037

Cite this

Ryan, C. E., Zon, R. L., Redd, R., Fisher, D. C., Shouval, R., Kumar, A., Crombie, J. L., Sadrzadeh, H., Kim, A. I., Nayak, L., Chukwueke, U. N., Jacobson, C. A., Frigault, M. J., Palomba, M. L., Armand, P., Epstein-Peterson, Z., & Merryman, R. W. (2023). Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. British Journal of Haematology, 203(5), 774-780. https://doi.org/10.1111/bjh.19037

@article{af18c29804ea4f9fa5211f211e1f486e,

title = "Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement",

abstract = "Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.",

keywords = "CNS, cellular therapies, non-Hodgkin lymphoma",

author = "Ryan, {Christine E.} and Zon, {Rebecca L.} and Robert Redd and Fisher, {David C.} and Roni Shouval and Anita Kumar and Crombie, {Jennifer L.} and Hossein Sadrzadeh and Kim, {Austin I.} and Lakshmi Nayak and Chukwueke, {Ugonma N.} and Jacobson, {Caron A.} and Frigault, {Matthew J.} and Palomba, {M. Lia} and Philippe Armand and Zachary Epstein-Peterson and Merryman, {Reid W.}",

note = "Publisher Copyright: {\textcopyright} 2023 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2023",

month = dec,

doi = "10.1111/bjh.19037",

language = "אנגלית",

volume = "203",

pages = "774--780",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

Ryan, CE, Zon, RL, Redd, R, Fisher, DC, Shouval, R, Kumar, A, Crombie, JL, Sadrzadeh, H, Kim, AI, Nayak, L, Chukwueke, UN, Jacobson, CA, Frigault, MJ, Palomba, ML, Armand, P, Epstein-Peterson, Z & Merryman, RW 2023, 'Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement', British Journal of Haematology, vol. 203, no. 5, pp. 774-780. https://doi.org/10.1111/bjh.19037

TY - JOUR

T1 - Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement

AU - Ryan, Christine E.

AU - Zon, Rebecca L.

AU - Redd, Robert

AU - Fisher, David C.

AU - Shouval, Roni

AU - Kumar, Anita

AU - Crombie, Jennifer L.

AU - Sadrzadeh, Hossein

AU - Kim, Austin I.

AU - Nayak, Lakshmi

AU - Chukwueke, Ugonma N.

AU - Jacobson, Caron A.

AU - Frigault, Matthew J.

AU - Palomba, M. Lia

AU - Armand, Philippe

AU - Epstein-Peterson, Zachary

AU - Merryman, Reid W.

PY - 2023/12

Y1 - 2023/12

N2 - Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.

AB - Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.

KW - CNS

KW - cellular therapies

KW - non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85168101138&partnerID=8YFLogxK

U2 - 10.1111/bjh.19037

DO - 10.1111/bjh.19037

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 37584155

AN - SCOPUS:85168101138

SN - 0007-1048

VL - 203

SP - 774

EP - 780

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this